Hypertension, Vol 14, 87-97, Copyright © 1989 by American Heart Association
AA Seymour, SA Fennell and JN Swerdel
Depressor and renal activities of atrial natriuretic factor-(99-126) were
determined in conscious, unrestrained spontaneously hypertensive rats
treated with a neutral endopeptidase inhibitor, SQ 29,072 (7-[[2-
(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]heptanoic acid). SQ 29,072 (100
mumol/kg i.v.) prolonged the transient depressor effects of the peptide for
as long as 2 hours. During the first hour after 3, 10, and 30 nmol/kg
atrial natriuretic factor, urinary excretion of cyclic 3'5' guanosine
monophosphate was significantly increased by 9.2 +/- 3.4, 13.0 +/- 2.2, and
12.7 +/- 4.2 nmol/kg/hr, respectively, in vehicle- treated rats and by 26.9
+/- 7.9, 52.1 +/- 11.1, and 46.4 +/- 12.2 nmol/kg/hr, respectively, in rats
given 100 mumol/kg SQ 29,072. During the first hour after 3 and 10 nmol/kg
atrial natriuretic factor-(99- 126), the sodium loss was 161 +/- 56 and 139
+/- 42 mueq/kg/hr in vehicle-treated rats and was significantly greater
(694 +/- 316 and 1,038 +/- 135 mueq/kg/hr) in rats given 100 mumol/kg SQ
29,072. After administration of 3, 10, and 30 mumol/kg SQ 29,072, the area
over the curves of the depressor responses to 3 nmol/kg of the peptide
increased from 297 +/- 70 to 306 +/- 108, 440 +/- 143, and 669 +/- 186 mm
Hg.min, respectively, while the concurrent natriuretic responses rose from
161 +/- 56 to 250 +/- 88, 332 +/- 142, 464 +/- 164, and 694 +/- 316
mueq/kg/hr. In summary, the neutral endopeptidase inhibitor SQ 29,072
increased the magnitudes and especially the durations of the depressor,
natriuretic, and cyclic guanosine monophosphate responses to exogenous
atrial natriuretic factor-(99-126) in conscious spontaneously hypertensive
rats, presumably by inhibition of degradation of atrial natriuretic factor
in vivo. In conclusion, neutral endopeptidase inhibition offers an
important new technique for enhancement and prolongation of the biological
lifetime of atrial natriuretic factor.
ARTICLES
Potentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29,072
Department of Pharmacology, Squibb Institute for Medical Research, Princeton, New Jersey 08540.
This article has been cited by other articles:
![]() |
K. H Chee, K. Amudha, N. A Hussain, H. K Haizal, A.-M. J Choy, and C. C Lang Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 140 - 148. [Abstract] [PDF] |
||||
![]() |
V. M. Campese, K. C. Lasseter, C. M. Ferrario, W. B. Smith, M. C. Ruddy, C. E. Grim, R. D. Smith, R. Vargas, M. F. Habashy, O. Vesterqvist, et al. Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients Hypertension, December 1, 2001; 38(6): 1342 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Chatelain, R. D. Ghai, A. J. Trapani, L. M. Odorico, B. N. Dardik, S. De Lombaert, R. W. Lappe, and C. A. Fink Antihypertensive and Natriuretic Effects of CGS 30440, a Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 974 - 982. [Abstract] [Full Text] |
||||
![]() |
A. A. Seymour, M. M. Asaad, J. H. Sheldon, P. L. Smith, and W. L. Rogers Atrial Natriuretic Peptide in Chronically Hypertensive Dogs Hypertension, October 1, 1995; 26(4): 634 - 641. [Abstract] [Full Text] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |